NCT02279407 - A Study to Investigate Effects of Omega-3 Carboxylic Acids and Dapagliflozin on Liver Fat Content in Diabetic Patients | Biotech Hunter

Enrollment

223

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2015

Study Completion Date

December 31, 2015

Conditions

T2 Diabetes and Fatty Liver Disease (Non-alcoholic Origin)

Interventions

DRUG

placebo

Placebo matching to Omega-3 carboxylic acids (olive oil)

DRUG

Omega-3 carboxylic acids

4 g administered as 4 x 1 g capsules

DRUG

Dapagliflozin

10 mg administered as 10 mg tablet

DRUG

Placebo

Placebo matching to dapagliflozin 10 mg

Trial Locations (5)

Research Site, Gothenburg

Research Site, Linköping

Research Site, Örebro

Research Site, Stockholm

Research Site, Uppsala